What Else in Gemcitabine-Pretreated Advanced Pancreatic Cancer? An Update of Second Line Therapies

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|5|1|43-56

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.5, Iss.1, 2010-01, pp. : 43-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 221-227

Karger

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 270-274

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 159-163

Karger

Access to resources Recommend Favorite

Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy

By  

Oncology Research and Treatment, Vol. 35, Iss. 10, 2012-09 ,pp. : 576-580

Karger

Access to resources Recommend Favorite

Multicenter Phase II Study of Gemcitabine and Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Colorectal Cancer Patients Pretreated with 5-Fluorouracil plus Irinotecan

By  

Oncology, Vol. 70, Iss. 2, 2006-05 ,pp. : 106-114

Karger

Access to resources Recommend Favorite